Recombinant parathyroid hormone in the management of osteoporosis

Calcified Tissue International

Volumn 77, Issue 2, 2005, Pages 65-71

  Compston, J ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; GLUCOCORTICOID; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; STRONTIUM RANELATE; TILUDRONIC ACID;

BONE DENSITY; BONE MASS; BONE REMODELING; BONE STRUCTURE; CLINICAL PRACTICE; CLINICAL TRIAL; DIZZINESS; DRUG EFFECT; DRUG SAFETY; FRAGILITY FRACTURE; HORMONAL THERAPY; HUMAN; LEG CRAMP; NAUSEA; NONHUMAN; ORTHOSTATIC HYPOTENSION; OSTEOLYSIS; OSTEOPOROSIS; OSTEOSARCOMA; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; RISK; VERTEBRA FRACTURE;

BONE AND BONES; BONE REMODELING; DIPHOSPHONATES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; OSTEOPOROSIS, POSTMENOPAUSAL; PARATHYROID HORMONE; PEPTIDE FRAGMENTS; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 27144530682     PISSN: 0171967X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00223-005-0012-0     Document Type: Review

References (48)

1. E Bauer J Aub F Albright 1929 Studies of calcium and phosphorus metabolism. V. A study of the bone trabeculae as a readily available reserve supply of calcium J Exp Med 49 145 162
2. J Reeve 1996 PTH: a future role in the management of osteoporosis J Bone Miner Res 11 440 445
3. DN Kalu J Pennock FH Doyle GV Foster 1971 Parathyroid hormone and experimental osteosclerosis Lancet i 1363 1366
4. J Reeve PJ Meunier JA Parsons M Bernat OLM Bijvoet P Courpron CM Edouard L Klenerman RM Neer JC Renier D Slovik FJFE Vismans JT Potts 1980 Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial B Med J 280 1340 1344
5. RM Neer CD Arnaud JR Zanchetta R Prince GA Gaich J-Y Reginster AB Hodsman EF Eriksen S Ish-Shalom HK Genant O Wang B Mitlak 2001 Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis New Engl J Med 344 1434 1441
6. Y Jiang JJ Zhao BH Mitlak O Wang HK Genant EF Eriksen 2003 Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure J Bone Miner Res 18 1932 1941
7. A Iida-Klein H Zhou SS Lu LR Levine M Ducayen-Knowles D Dempster J Nieves R Lindsay 2002 Anabolic action of parathyroid hormone is skeletal site specific at the tissue and cellular levels in mice J Bone Miner Res 17 808 816
8. JM Hock 2001 Anabolic actions of PTH in the skeleton of animals J Musculoskel Neuron Interact 2 33 47
9. AB Hodsman B Steer 1993 Early histomorphometric changes in response to parathyroid hormone in osteoporosis: evidence for de novo bone formation on quiescent surfaces Bone 14 523 527
10. DW Dempster F Cosman ES Kurland H Zhou J Nieves L Woelfert E Shane K Plavetic R Müller JP Bilezikian R Lindsay 2001 Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study J Bone Miner Res 16 1846 1853
11. DW Dempster H Zhou F Cosman J Nieves JD Adachi LJ Fraher PH Watson R Lindsay AB Hodsman 2001 PTH treatment directly stimulates bone formation in cancellous and cortical bone in humans J Bone Miner Res 16 S179
12. AM Parfitt 2002 Perspective. Parathyroid hormone and periosteal bone expansion J Bone Miner Res 17 1741 1743
13. JR Zanchetta CE Bogado JL Ferretti O Wang MG Wilson M Sato GA Gaich GP Dalsky SL Myers 2003 Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis J Bone Miner Res 18 539 543
14. DB Burr T Hirano CH Turner C Hotchkiss R Brommage JM Hock 2001 Intermittently administered human parathyroid hormone (1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomised cynomolgus monkeys J Bone Miner Res 16 157 165
15. RL Jilka RS Weinstein T Bellido P Robertson AM Parfitt SC Manolagas 1999 Increased bone formation by prevention of osteoblast apoptosis with PTH J Clin Invest 104 439 446
16. JM Hock V Krishnan JE Onyia JP Bidwell J Milas D Stanilaus 2001 Perspective. Osteoblast apoptosis and bone turnover J Bone Miner Res 16 975 984
17. J-J Body GA Gaich WH Scheele PM Kulkarni PD Miller A Peretz RK Dore R Correa-Rotter A Papaioannou DC Gumming AB Hodsman 2002 A randomised double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis J Clin Endocrinol Metab 87 4528 4535
18. DM Black SL Greenspan KE Ensrud L Palermo JA McGowan TF Lang P Garnero ML Bouxsein JP Bilezikian CJ Rosen 2003 The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis New Engl J Med 349 1207 1215
19. ES Orwoll WH Scheele S Paul S Adami U Syversen A Diez-Perez JM Kaufman AD Clancy GA Gaich 2003 The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis J Bone Miner Res 18 9 17
20. AB Hodsman BM Steer LJ Fraher DJ Drost 1991 Bone densitometric and histomorphometric responses to sequential human parathyroid hormone (1-38) and salmon calcitonin in osteoporotic patients Bone Miner 14 67 83
21. RM Neer DM Slovik M Daly JT Potts SR Nussbaum 1993 Treatment of postmenopausal osteoporosis with daily parathyroid hormone plus calcitriol Osteoporos Int 3 204 205
22. R Lindsay J Nieves CA Formica E Henneman L Woelfert V Shen DW Dempster F Cosman 1997 Randomised controlled study of effects of parathyroid hormone on vertebral bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis Lancet 350 550 555
23. JS Finkelstein A Klibanski AL Arnold TL Toth RM Neer 1998 Prevention of estrogen deficiency related bone loss with human parathyroid hormone (1-34): a randomised controlled trial JAMA 280 1067 1076
24. AB Hodsman DA Hanley MP Ettinger MA Bolognese J Fox AJ Metcalfe R Lindsay 2003 Efficacy and safety of human parathyroid hormone-(l-84) in increasing bone mineral density in postmenopausal osteoporosis J Clin Endocrinol Metab 88 5212 5220
25. R Marcus O Wang J Satterwhite B Mitlak 2003 The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis J Bone Miner Res 18 18 23
26. Forsteo Summary of product characteristics
27. BM Misof P Roschger F Cosman ES Kurland W Tesch P Messmer DW Dempster J Nieves E Shane P Fratzl K Klaushofer JP Bilezikian R Lindsay 2003 Effects of intermittent parathyrouid hormone administration on bone mineralisation density in iliac crest biopsies from patients with osteoporosis: a paired study before and after treatment J Clin Endocrinol Metabol 88 1150 1156
28. JL Vahle M Sato GG Long JK Young PC Francis JA Engelhardt M Westmore L Ma JB Nold 2002 Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety Toxicol Pathol 30 312 321
29. PC Jutte R Rosso M de Paolis C Errani E Pasini L Campanacci G Bacci F Bertoni M Mercuri 2004 Osteosarcoma associated with hyperparathyroidism Skeletal Radiol 33 473 476
30. AH Tashjian BA Chabner 2002 Perspective. Commentary on clinical safety of recombinant human parathyroid hormone 1-34 in the treatment of osteoporosis in men and postmenopausal women J Bone Miner Res 17 1151 1161
31. NE Lane S Sanchez GW Modin HK Genant CD Arnaud 1998 Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled trial J Clin Invest 102 1627 1633
32. NE Lane S Sanchez GW Modin HK Genant E Pierini CD Arnaud 2000 Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial J Bone Miner Res 15 944 951
33. JM Hock J Hummert R Boyce J Fonseca LG Raisz 1989 Resorption is not essential for the stimulation of bone formation by human PTH 1-34 in rats in vivo J Bone Miner Res 4 449 458
34. PD Delmas P Vergnaud ME Arlot P Pastoureau PJ Meunier MHL Nilssen 1995 The anabolic effect of human PTH (1-34) on bone formation is blunted when bone resorption is inhibited by the bisphosphonate tiludronate -is activated resorption a prerequisite for the in vivo effect of PTH on formation in a remodelling system? Bone 16 603 610
35. JS Finkelstein A Hayes JL Hunzelman JJ Wyland H Lee RM Neer 2003 The effects of parathyroid hormone, alendronate, or both in men with osteoporosis N Engl J Med 349 1216 1226
36. F Cosman J Nieves L Woelfert CA Formica SL Gordon V Shen R Lindsay 2001 Parathyroid hormone added to established hormone replacement therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal J Bone Miner Res 16 925 931
37. F Cosman J Nieves L Woelfert V Shen R Lindsay 1998 Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic woman J Bone Miner Res 13 1051 1055
38. B Ettinger J San Martin G Grans I Pavo 2004 Differential effects of teriparatide on BMP after treatment with raloxifene or alendronate J Bone Miner Res 19 745 751
39. RS Rittmaster M Bolognes MP Ettinger DA Hanley AD Hodsman DL Kendler CJ Rosen 2000 Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate J Clin Endocrinol Metab 85 2129 2134
40. R Lindsay W Scheele N Neer G Pohl S Adami C Mautalen J-Y Reginster JJ Stepan SL Myers BH Mitlak 2004 Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis Arch Intern Med 164 2024 2030
41. DM Black SR Cummings DB Karpf JA Cauley DE Thompson MC Nevitt DC Bauer HK Genant WL Haskell R Marcus SM Ott JC Torner SA Quandt TF Reiss KE Ensrud 1996 Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures Lancet 348 1535 1541
42. B Ettinger DM Black BH Mitlak RK Knickerbocker T Nickelsen HK Genant C Christiansen PD Delmas JR Xanchetta J Stakkestad CC Glüer K Krueger FJ Cohen S Eckert KE Ensrud LV Avioli P Lips SR Cummings 1999 Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial JAMA 282 637 645
43. ST Harris NB Watts HK Genant CD McKeever T Hangartner M Keller CH Chesnut J Brown EF Eriksen MS Hoseyni DW Axelrod PD Miller 1999 Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. A randomized controlled trial JAMA 282 1344 1352
44. J-Y Reginster HW Minne OH Sorensen M Hooper C Roux ML Brandi B Lund D Ethgen S Pack I Roumagnac R Eastell on behalf of the Vertebral Efficacy with Risedronate Therapy (VERT) Study Group 2000 Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis Osteoporos Int 11 83 91
45. CH Chesnut S Silverman K Andriano HK Genant A Gimona S Harris D Kiel M LeBoff M Maricic N Watts D Baylink 2000 A randomised trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the Prevent Recurrence of Osteoporotic Fractures Study Am J Med 109 267 276
46. PJ Meunier C Roux E Seeman S Ortolani JE Badurski TD Spector J Cannata A Balogh EM Lemmel S Pors-Nielsen R Rizzoli HK Genant JY Reginster 2004 The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis N Engl J Med 350 459 468
47. MR McClung P Geusens PD Miller H Zippel WG Benson C Roux S Adami I Fogelman T Diamond R Eastell PJ Meunier J-Y Reginster 2001 Effect of risedronate on the risk of hip fracture in elderly women N Engl J Med 344 333 340
48. JY Reginster E Seeman MC DeVernejoul S Adami J Compston C Phenekos JP Devogelaer M Diaz-Curiel A Sawicki S Goemare OH Sorensen D Felsenberg PJ Meunier 2005 Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of peritoneal osteoporosis (TROPOS) study. J Clin Endocrinol Metab 90 2816